NeuroBo Pharmaceuticals (NRBO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

NRBO NeuroBo Pharmaceuticals

Watchlist

2.2200
-0.1700-7.11%

Close Nov 15 16:00 ET

2.1900
-0.0300-1.35%

Post 20:01 ET

19.13MMarket Cap-517P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Watching NeuroBo Pharmaceuticals; Zacks Small-Cap Research Gives Stock $22 Price Valuation
BenzingaNov 13 12:58 ET
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November
PR NewswireNov 13 08:01 ET
NeuroBo Pharmaceuticals: Promising MASH and Obesity Treatment Pipeline Driving Buy Rating
TipRanksNov 8 13:15 ET · Ratings
NeuroBo Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
SECNov 7 16:14 ET · Announcements
Express News | NeuroBo Pharmaceuticals Q3 2024 GAAP EPS $(0.55) Beats $(0.73) Estimate
BenzingaNov 7 08:23 ET
Express News | NeuroBo Pharmaceuticals: Cash Was Approximately $21.7 Million as of September 30, 2024
ReutersNov 7 08:04 ET

Comments

Trytosaveabit

Nov 4 07:03

Make a note!

$NeuroBo Pharmaceuticals (NRBO.US)$ Reuters· 1 min ago
NeuroBo Pharmaceuticals Inc - Topline Data Readout Expected in December 2024

Stock_Drift

Oct 4 08:37

Low Floats. 9:35am EST. 10/4/24

$Guardion Health Sciences (Delisted) (GHSI.US)$ $Pasithea Therapeutics (KTTA.US)$ $Zeo Energy (ZEO.US)$ $Foxx Development Holdings (FOXX.US)$ $Entero Therapeutics (ENTO.US)$ $NeuroBo Pharmaceuticals (NRBO.US)$ $Draganfly (DPRO.US)$ $Power REIT (PW.US)$ $Nuburu (BURU.US)$ $JBDI Holdings (JBDI.US)$ $Aditxt (ADTX.US)$ $Beneficient (BENF.US)$

Jaguar8

Sep 30 07:08

NEWS

$NeuroBo Pharmaceuticals (NRBO.US)$
NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals (Nasdaq: NRBO) announced positive top-line data from Part 1 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog agonist for obesity treatment. The single ascending dose (SAD) study revealed favorable safety, tolerability, and dose-linear pharmacoki...

Trytosaveabit

Sep 30 07:03

News

$NeuroBo Pharmaceuticals (NRBO.US)$ Reuters· 1 min ago
NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the Sad Part 1 of Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity